EUVIMEDEUVIMED entdecken
Crossref

Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer

Lisa Isoda, Emiko Sonoda-Fukuda, Hiroaki Fujino, Toru Takarada, Kosei Hasegawa, Noriyuki Kasahara, Shuji Kubo

Anticancer Research · 2023

DOI: 10.21873/anticanres.16734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Lisa Isoda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya, Japan. Hauptthemen laut MEDLINE: Prodrugs, Ovarian Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsOvarian NeoplasmsAnimalsMiceHumansFemaleCell Line, TumorSaccharomyces cerevisiaeCytosine DeaminaseFlucytosineMice, NudeHEK293 CellsGenetic TherapyLeukemia Virus, Gibbon ApeGenetic Vectors

Stichwörter der Autor:innen

Ovarian canceramphotropic murine leukemia viruscancer virotherapygibbon ape leukemia virusprodrug activator gene therapyretroviral replicating vectors

Substanzen

ProdrugsCytosine DeaminaseFlucytosine

Autor:innen und Institutionen

  • Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya, Japan.
  • Department of Biomedical Chemistry, School of Science and Technology, Kwansei Gakuin University, Sanda, Japan.
  • Laboratory of Functional Molecular Chemistry, Kobe Pharmaceutical University, Kobe, Japan.
  • Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
  • Departments of Neurological Surgery and Radiation Oncology, University of California, San Francisco, CA, U.S.A.
  • Laboratory of Molecular and Genetic Therapeutics, Institute of Advanced Medical Science, Hyogo Medical University, Nishinomiya, Japan; s-kubo@hyo-med.ac.jp.

Zitieren

APA

Isoda, L., Sonoda-Fukuda, E., Fujino, H., Takarada, T., Hasegawa, K., Kasahara, N., & Kubo, S. (2023). Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.16734

Vancouver

Isoda L, Sonoda-Fukuda E, Fujino H, Takarada T, Hasegawa K, Kasahara N, et al. Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer. Anticancer Research. 2023. doi:10.21873/anticanres.16734

BibTeX
@article{Isoda2023,
  author = {Isoda, Lisa and Sonoda-Fukuda, Emiko and Fujino, Hiroaki and Takarada, Toru and Hasegawa, Kosei and Kasahara, Noriyuki and Kubo, Shuji},
  title = {Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16734}
}
Kostenlos starten →